723 related articles for article (PubMed ID: 35858709)
1. Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects.
Peters S; Paz-Ares L; Herbst RS; Reck M
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858709
[TBL] [Abstract][Full Text] [Related]
2. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
3. Comprehensive Review: Unveiling the Pro-Oncogenic Roles of IL-1ß and PD-1/PD-L1 in NSCLC Development and Targeting Their Pathways for Clinical Management.
Castillo DR; Jeon WJ; Park D; Pham B; Yang C; Joung B; Moon JH; Lee J; Chong EG; Park K; Reeves ME; Duerksen-Hughes P; Mirshahidi HR; Mirshahidi S
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511306
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
Front Immunol; 2022; 13():974581. PubMed ID: 36159860
[TBL] [Abstract][Full Text] [Related]
5. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
6. Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer.
Villaruz LC; Blumenschein GR; Otterson GA; Leal TA
Cancer; 2023 May; 129(9):1319-1350. PubMed ID: 36848319
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylserine Sensing by TAM Receptors Regulates AKT-Dependent Chemoresistance and PD-L1 Expression.
Kasikara C; Kumar S; Kimani S; Tsou WI; Geng K; Davra V; Sriram G; Devoe C; Nguyen KN; Antes A; Krantz A; Rymarczyk G; Wilczynski A; Empig C; Freimark B; Gray M; Schlunegger K; Hutchins J; Kotenko SV; Birge RB
Mol Cancer Res; 2017 Jun; 15(6):753-764. PubMed ID: 28184013
[TBL] [Abstract][Full Text] [Related]
8. MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.
He K; Berz D; Gadgeel SM; Iams WT; Bruno DS; Blakely CM; Spira AI; Patel MR; Waterhouse DM; Richards DA; Pham A; Jotte R; Hong DS; Garon EB; Traynor A; Olson P; Latven L; Yan X; Shazer R; Leal TA
J Thorac Oncol; 2023 Jul; 18(7):907-921. PubMed ID: 36842467
[TBL] [Abstract][Full Text] [Related]
9. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
[TBL] [Abstract][Full Text] [Related]
10. Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data.
So WV; Dejardin D; Rossmann E; Charo J
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822668
[TBL] [Abstract][Full Text] [Related]
11. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
[TBL] [Abstract][Full Text] [Related]
12. Programmed death-ligand 1 expression in non-small cell lung carcinoma - mechanism of regulation, association with other markers, and therapeutic implication.
Tancoš V; Blichárová A; Plank L
Klin Onkol; 2022; 35(5):372-376. PubMed ID: 36443097
[TBL] [Abstract][Full Text] [Related]
13. First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions.
Ackermann CJ; Adderley H; Ortega-Franco A; Khan A; Reck M; Califano R
Drugs; 2020 Nov; 80(17):1783-1797. PubMed ID: 32986224
[TBL] [Abstract][Full Text] [Related]
14. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.
Aggarwal C; Prawira A; Antonia S; Rahma O; Tolcher A; Cohen RB; Lou Y; Hauke R; Vogelzang N; P Zandberg D; Kalebasty AR; Atkinson V; Adjei AA; Seetharam M; Birnbaum A; Weickhardt A; Ganju V; Joshua AM; Cavallo R; Peng L; Zhang X; Kaul S; Baughman J; Bonvini E; Moore PA; Goldberg SM; Arnaldez FI; Ferris RL; Lakhani NJ
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35414591
[TBL] [Abstract][Full Text] [Related]
15. Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment.
Myers KV; Amend SR; Pienta KJ
Mol Cancer; 2019 May; 18(1):94. PubMed ID: 31088471
[TBL] [Abstract][Full Text] [Related]
16. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
17. Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition.
Engelsen AST; Lotsberg ML; Abou Khouzam R; Thiery JP; Lorens JB; Chouaib S; Terry S
Front Immunol; 2022; 13():869676. PubMed ID: 35572601
[TBL] [Abstract][Full Text] [Related]
18. TAM family kinases as therapeutic targets at the interface of cancer and immunity.
DeRyckere D; Huelse JM; Earp HS; Graham DK
Nat Rev Clin Oncol; 2023 Nov; 20(11):755-779. PubMed ID: 37667010
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
20. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL
Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]